Press Releases

Management to host conference call and webcast at 5:00 p.m. ET on that day DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled medical transportation and mobile health services, announced today that the Company will release its financial results for the first quarter ended March 31, 2026 after the markets close on Monday, May 11, 2026. Management will also host a conference call to discuss these results at 5:00 p.m. ET on that day. Conference call and webcast details: Monday, May 11, 2026 5:00 p.m. ET 1-800-717-1738 (U.S.) 1-646-307-1865 (international) Conference ID: 15300 To access the Call me™ feature, which avoids the need to wait for an

Toronto, Ontario--(Newsfile Corp. - April 27, 2026) - Seabridge Gold Inc. (TSX:SEA) (NYSE:SA) ("Seabridge" or the "Company") provides a further update to its announcements in December 2025 and January 2026 regarding the Company's intention to spin out its 100% interest in the Courageous Lake gold project (the "Courageous Lake Project") located in the Northwest Territories, Canada into a separate listed entity, Valor Gold Corp ("Valor"), with 100% of the common shares of Valor ("Valor Shares") being distributed by Seabridge to its shareholders ("Shareholders") by way of a plan of arrangement under the Canada Business Corporations Act (the "Arrangement").On January 21, 2026, the Company provid

Boca Raton, Florida--(Newsfile Corp. - April 27, 2026) - Atlas Lithium Corporation (NASDAQ:ATLX) ("Atlas Lithium" or the "Company"), a leading developer of lithium resources, is pleased to announce the engagement of key operational partners for the implementation of its 100%-owned Neves Project. Several qualified firms participated in a competitive selection process led by Atlas Lithium's technical team. Contracts were awarded based on a comprehensive evaluation of relevant criteria, including technical experience, proven performance, quality, and cost efficiency. Each awarded contract was finalized at or below the budget projections outlined in the Company's Definitive Feasibility Study (th

LAUSANNE, Switzerland, April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Monday, May 4, 2026, at 8:30 a.m. EDT to report financial results for the first quarter of 2026 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event,

Capital Markets Strategy / Technology Platform ExpansionBOISBRIAND, QC, April 27, 2026 /PRNewswire/ -- Vision Marine Technologies Inc. (NASDAQ:VMAR) ("Vision Marine" or the "Company"), a company developing high-voltage electric marine propulsion systems and operating a growing recreational boating platform, today announced that it has received conditional approval to list its common shares on the TSX Venture Exchange ("TSXV"), further expanding its capital markets presence across North America. Vision Marine is currently working with the TSXV to complete the final steps of the l

SAN RAFAEL, Calif., April 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, May 4, 2026, at 4:30 p.m. ET to discuss first quarter 2026 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 800-715-9871International Dial-in Number: 646-307-1963Conference Call ID: 3424435 U.S. / Canada Replay Dial-in Number: 800-770-2030International Replay Dial-in Number: 609-800-9909Playback I

All Three Proxy Advisory Firms Have Now Recommended For Impactive Nominees and Highlighted the Need for Greater Independent Oversight in the WEX Boardroom ISS Recommends Shareholders Vote FOR Impactive Nominees Kurt Adams and Lauren Taylor Wolfe and WITHHOLD Support on WEX Directors Nancy Altobello and Stephen Smith Highlights the "Disconnect" Between Board's Portrayal of Performance and Company Track Record That Raises "Credible Questions" About Its Willingness to Hold Management Accountable Concludes WEX Board Would Benefit From the Addition of a Significant Shareholder Representative, Greater Independence and Enhanced Industry Experience Impactive Urges Shareholders to Vote on th

Financing Led by Oaktree Capital with Participation from Two Seas Capital and Other New and Existing Institutional Investors Today, SharonAI Holdings Inc. (NASDAQ:SHAZ) and its subsidiaries ("Sharon AI" or "the Company"), a leading Australian Neocloud, announced that it has entered into definitive agreements for the purchase of US$350 million of 6% Convertible Senior Notes due in 2031 (the "Notes"). The issue price for the Notes will equal 100% of the principal amount thereof. The Notes will be sold in a private offering pursuant to Rule 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act") to persons reasonably believed to be qualified institutional buyers in reliance

— Published 3-year Post-Approval Study results show 82% median seizure reduction in drug-resistant focal epilepsy — — American Academy of Neurology (AAN) presentation featured 12- and 18-month NAUTILUS data, the first randomized controlled trial of neuromodulation in drug-resistant idiopathic generalized epilepsy (IGE) — — Growing body of high-quality clinical evidence reinforces the RNS System's differentiated position across focal and generalized epilepsy — NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a major milestone in its clinical evidence program with the publication of 3

LAFAYETTE, Colo., April 27, 2026 (GLOBE NEWSWIRE) -- urban-gro, Inc. (NASDAQ:UGRO) ("urban-gro" or the "Company"), which operates its sports and media business under the Flash brand, today is providing a comprehensive business update to investors regarding (i) the Company's strategic transition into a sports, media, and experiential marketing platform, (ii) the restoration of its Nasdaq listing compliance as previously disclosed in Forms 8-K, (iii) the Company's near-term operating focus around Lanka Premier League ("LPL") Season 6, and (iv) strategic context for the Company's cricket platform, including and separately, the inclusion of cricket at the Los Angeles 2028 Olympic Games and the

Eric Andersen to Become Chief Executive Officer of AIG and join the Board of Directors on June 1st Peter Zaffino To Become Executive Chair of the AIG Board of Directors The AIG Board of Directors announced today that effective June 1, 2026, Eric Andersen will become President and Chief Executive Officer of AIG and join the AIG Board of Directors and Peter Zaffino will become Executive Chair of the AIG Board of Directors, marking the successful conclusion of the company's previously announced leadership transition plan. "I want to express my appreciation and gratitude to Peter Zaffino for his tremendous leadership, tireless commitment and contributions in transforming AIG and restoring

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of median progression-free survival (PFS) of 4.7 months versus 2.6 months, providing a 56% reduction in the risk of progression (hazard ratio=0.44, p<0.0001). Secondary endpoint analyses of overall survival (OS) were confounded by both high crossover (54%) and notably prolonged survival in crossover patients randomized to the control arm then treated with tovecimig and, therefore, did not meet statistical significance. In a subset analysis of the patients in the control arm, the median OS of the crosso

PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced that CEO Dr. Raza Bokhari, along with the Medicus leadership team, conducted a series of meetings on Capitol Hill with senior lawmakers across key healthcare committees to advance support for: Orphan Drug Designation for SkinJect® for Gorlin SyndromeRegistrational Investigation New Drug (IND) approval for Gorlin Syndrome patientsRare disease pediatric FDA voucher program These engagements included: Brett Guthrie — Chai

– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 – – Study showed favorable benefit for toxicity related discontinuations and drug-drug interactions – – Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens – PARSIPPANY, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin for injection) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic hematopoietic stem cell transplantation (H

Warsaw, Poland and Taipei, Taiwan, April 27, 2026 (GLOBE NEWSWIRE) -- CADV Ventures S.A., an AI software company founded in 2017 and headquartered in Warsaw, Poland, focused on improving digital customer engagement for large organizations ("CADV.AI"), and Miluna Acquisition Corp (NASDAQ:MMTX) ("Miluna"), a special purpose acquisition company, today announced that they have entered into a definitive business combination agreement. Upon closing of the proposed business combination, the combined company will operate under the name Kukugan Corp., a Cayman Islands exempted company, and the combined company's ordinary shares and warrants are anticipated to be listed on a national securities exch

Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presentedBiomarker analyses from the ongoing Phase 3 study evaluating predictors of response PHILADELPHIA and VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce three clinical data poster presentations and three publication-only abstracts at the 2026 ASCO Annual Meeting, taking place May 29-June 2, 2026 at McCormick Place, Chicago, Illinois. The details of the poster presentation sessions and

Management to Highlight Strategic Transformation, Live Event Growth and 2026 Outlook - OVERLAND PARK, Kan., April 27, 2026 (GLOBE NEWSWIRE) -- Kustom Entertainment, Inc. (NASDAQ:KUST), a leader in live event production and ticketing technology, today announced that Chief Executive Officer Stanton E. Ross will present at the 16th Annual LD Micro Invitational, taking place May 17–19, 2026, at the Luxe Sunset Blvd. Hotel in Los Angeles, California. At LD Micro, Kustom plans to outline the strategic progress driving its evolution into a more focused live entertainment and ticketing company. Topics expected to be highlighted during the presentation include: January 2026 rebrand to Kustom Ent

VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced the appointment of Keith Vendola, MD, MBA, as Chief Financial Officer (CFO), effective immediately. Dr. Vendola will lead the Company's financial strategy and operations, including capital markets activity, financial planning, corporate development and supporting strategic initiatives. "We are thrilled to welcome Keith, an accomplished leader with deep operational and f

Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities IND application expected to be filed in first half of 2027 to seek authorization for clinical study in patients with pancreatic cancer Poster presented at the American Association of Cancer Research Annual Meeting 2026 MIRAMAR, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation announced today major development regarding

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Keel Infrastructure Corp. (NASDAQ/TSX:KEEL) ("Keel Infrastructure" or "Keel"), a North American digital and energy infrastructure company, will report its first quarter 2026 financial results on Monday, May 11 before the market opens. Management will host a conference call on the same day at 8:00 am Eastern. Q1 2026 materials will be available before the call and can be accessed on the ‘Quarterly Results' section of the Keel investor site. The live webcast and a webcast replay of the conference call can be accessed here. To access the call by telephone, register here to receive dial-in numbers and a unique PIN to join the call. About Keel Infr